Circulating MicroRNAs: Possible Prediction Biomarkers for Personalized Therapy of Non–Small-Cell Lung Carcinoma
- 1 January 2011
- journal article
- review article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 12 (1), 14-17
- https://doi.org/10.3816/clc.2011.n.001
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosisBiomedicine & Pharmacotherapy, 2010
- MicroRNA Signature Predicts Survival and Relapse in Lung CancerCancer Cell, 2008
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006
- Unique microRNA molecular profiles in lung cancer diagnosis and prognosisCancer Cell, 2006
- MicroRNAs as oncogenesCurrent Opinion in Genetics & Development, 2006
- RAS Is Regulated by the let-7 MicroRNA FamilyCell, 2005
- Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancerEuropean Journal of Cancer, 2005
- Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer GroupJournal of Clinical Oncology, 2005
- Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative SurvivalCancer Research, 2004